Abstract A37: Targeting RAGE in pancreatic cancer using monoclonal antibodies

Abstract

Recent studies suggest that the Receptor for Advanced Glycation End Products (RAGE) and its ligands (S100P or HMGB1) are important contributors to the progression of pancreatic cancer. Being a cell surface receptor, RAGE possesses a large extracellular domain that binds its activating ligands. We reasoned that monoclonal antibodies that block the interaction between RAGE and its ligands could impact the progression of pancreatic cancer. We have generated a panel of antibodies recognizing different domains of the receptor and are currently testing their inhibitory effects, in pancreatic cancer cells and in small animal models. Citation Format: Priyanka Swami, Venkata Indurthi, Stefan W. Vetter, Estelle Leclerc.{Authors}. Targeting RAGE in pancreatic cancer using monoclonal antibodies. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr A37.